A phase 2 trial investigating the effects of the angiotensin II type 2 receptor agonist C21 in systemic sclerosis-related Raynaud's
Ariane L Herrick, Rohit Batta, Kamilla Overbeck, Johan Raud, Joanne Manning, Andrea Murray, Graham Dinsdale, Göran Tornling, Ariane L Herrick, Rohit Batta, Kamilla Overbeck, Johan Raud, Joanne Manning, Andrea Murray, Graham Dinsdale, Göran Tornling
Abstract
Objective: Our main aim was to investigate the effect of a single oral dose of C21, a selective angiotensin II type 2 receptor agonist, on cold-induced vasoconstriction in SSc-related RP.
Methods: This was a phase IIa, randomized, double-blind, cross-over, single-dose, placebo-controlled, single-centre study. Twelve female patients with SSc (median age 58.5 years, median duration of RP 19.0 years) attended on four occasions: screening, treatment visits 1 and 2 (separated by 3-7 days) and follow-up. At the first treatment visit, patients were randomized to receive either a single oral dose of C21 (200 mg) or placebo, then the opposite treatment on the second visit. Forty min after each treatment, each patient underwent a standard hand cold challenge. The primary end point was the area under the curve (AUC) for rewarming for each finger (eight fingers) over 15 min. Secondary end points included the maximum finger temperature after rewarming (MAX). Statistical analyses were performed by multiplicative ANCOVA models.
Results: For all eight fingers combined, mean AUC for rewarming was higher after treatment with C21 than after placebo (geometric mean 20 046°C*s vs 19 558°C*s), but not significantly (P = 0.380) and MAX (at 15 min) was also higher (geometric mean 23.5°C vs 22.5°C; P = 0.036). C21 was well tolerated.
Conclusion: Despite the small trial size, a signal emerged suggesting that even in patients with established SSc, C21 may confer benefit for RP and deserves further investigation.
Trial registration: ClinicalTrials.gov, https://ichgcp.net/clinical-trials-registry/NCT04388176" title="See in ClinicalTrials.gov">NCT04388176.
Keywords: RP; SSc; angiotensin II type 2 receptor agonist; randomized controlled trial; thermography.
© The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology.
Figures
References
- Elhai M, Avouac J, Walker UA. et al. A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. Ann Rheum Dis 2016;75:163–9.
- Herrick AL. The pathogenesis, diagnosis and treatment of Raynaud phenomenon. Nat Rev Rheumatol 2012;8:469–79.
- Kowal-Bielecka O, Fransen J, Avouac J. et al.; EUSTAR Coauthors. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 2017;76:1327–39.
- Khouri C, Lepelley M, Bailly S. et al. Comparative efficacy and safety of treatments for secondary Raynaud’s phenomenon: a systematic review and network meta-analysis of randomised trials. Lancet Rheumatol 2019;1:e237–46.
- Frantz C, Avouac J, Distler O. et al. Impaired quality of life in systemic sclerosis and patient perception of the disease: large international survey. Semin Arthritis Rheum 2016;46:115–23.
- Forrester SJ, Booz GW, Sigmund CD. et al. Angiotensin II signal transduction: an update on mechanisms of physiology and pathophysiology. Physiol Rev 2018;98:1627–738.
- Schinzari F, Tesauro M, Rovella V. et al. Coexistence of functional angiotensin II type 2 receptors mediating both vasoconstriction and vasodilation in humans. J Hypertens 2011;29:1743–8.
- Savoia C, Touyz RM, Volpe M, Schiffrin EL.. Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients. Hypertension 2007;49:341–6.
- Lang JA, Krajek AC.. Age-related differences in the cutaneous vascular response to exogenous angiotensin II. Am J Physiol Heart Circ Physiol 2019;316:H516–21.
- Peluso AA, Bertelsen JB, Andersen K. et al. Identification of protein phosphatase involvement in the AT2 receptor-induced activation of endothelial nitric oxide synthase. Clin Sci (Lond) 2018;132:777–90.
- Steckelings UM, Wollschlager T, Peters J. et al. Human skin: source of and target organ for angiotensin II. Exp Dermatol 2004;13:148–54.
- Kawaguchi Y, Takagi K, Hara M. et al. Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors. Arthritis Rheum 2004;50:216–26.
- Wan Y, Wallinder C, Plouffe B. et al. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem 2004;47:5995–6008.
- Merkel PA, Herlyn K, Martin RW. et al.; Scleroderma Clinical Trials Consortium. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum 2002;46:2410–20.
- Berks M, Dinsdale G, Murray A. et al. Automated structure and flow measurement – a promising tool in nailfold capillaroscopy. Microvasc Res 2018;118:173–7.
- Wilkinson JD, Leggett SA, Marjanovic EJ. et al. A multicenter study of the validity and reliability of responses to hand cold challenge as measured by laser speckle contrast imaging and thermography: outcome measures for systemic sclerosis-related Raynaud's Phenomenon. Arthritis Rheumatol 2018;70:903–11.
- van den Hoogen F, Khanna D, Fransen J. et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2013;65:2737–47.
- Dziadzio M, Denton CP, Smith R. et al. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 1999;42:2646–55.
- Sumners C, de Kloet AD, Krause EG, Unger T, Steckelings UM.. Angiotensin type 2 receptors: blood pressure regulation and end organ damage. Curr Opin Pharmacol 2015;21:115–21.
- Barber MN, Sampey DB, Widdop RE.. AT2 receptor stimulation enhances antihypertensive effect of AT1 receptor antagonist in hypertensive rats. Hypertension 1999;34:1112–6.
Source: PubMed